Losartan Potassium
Product Images NDC 50090-5337

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 50090-5337). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image001 (03375ec9 0e3a 40c2 8c77 De5d9fd21876 01)

Chemical structure of losartan potassium, showing the molecular arrangement including chlorinated and hydroxyl groups, aromatic rings, and a potassium cation.*

FDA Label Image

Image002 (03375ec9 0e3a 40c2 8c77 De5d9fd21876 02)

A line graph comparing the percentage of patients with a primary endpoint over study months for Atenolol (dotted line) versus Losartan potassium (solid line). The x-axis represents study months up to 66, and the y-axis shows the percentage of patients up to 16%. The graph notes an adjusted risk reduction of 13% with a p-value of 0.021.*

FDA Label Image

Image003 (03375ec9 0e3a 40c2 8c77 De5d9fd21876 03)

A step plot chart comparing the percentage of patients experiencing fatal or non-fatal stroke over study months up to 66 months, showing two treatment groups: Atenolol (dotted line) and Losartan potassium (solid line). The x-axis represents study months, and the y-axis shows the percentage of patients. Text on the chart notes an adjusted risk reduction of 25% with Losartan potassium (p=0.001).*

FDA Label Image

Image004 (03375ec9 0e3a 40c2 8c77 De5d9fd21876 04)

A forest plot chart comparing event rates (%) and hazard ratios with 95% confidence intervals for Losartan Potassium and Atenolol. The chart is divided into two sections: Primary Composite and Stroke (Fatal/Non-fatal), each showing overall results and subgroups by age, gender, race, ISH status, diabetes, and history of cardiovascular disease (CVD). The horizontal axis measures hazard ratios, indicating whether the data favors Losartan Potassium or Atenolol.*

FDA Label Image

Image005 (03375ec9 0e3a 40c2 8c77 De5d9fd21876 05)

A line chart showing the percentage of patients with events over a 48-month period, comparing Losartan potassium to placebo. The chart indicates a risk reduction of 16.1% with Losartan potassium and includes a p-value of 0.022. The x-axis is labeled 'Months' and the y-axis is labeled '% patients with event.'*

FDA Label Image

Label Image (Lbl500905337)

Packaging label for LOSARTAN POTASSIUM 100 mg tablets by A-S Medication Solutions. The label specifies each tablet contains 100 mg of losartan potassium. It instructs to store the product at 77 degrees Fahrenheit, protect it from light, and notes the container has 90 film-coated tablets. The label includes a NDC number 50090-5337 and manufacturing information from Vivimed Life Sciences PR.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.